Large Benefit From Ovarian Function Suppression in Breast Cancer Large Benefit From Ovarian Function Suppression in Breast Cancer
Eight-year follow-up of the ASTRRA trial confirms and extends support for adding 2 years of ovarian function suppression with goserelin to tamoxifen, compared with tamoxifen alone.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | Ovarian Cancer | Ovaries | Tamoxifen